CVS HEALTH CORPORATION REPORTS FOURTH QUARTER AND FULL-YEAR 2024 RESULTS

Go back to CVS HEALTH CORPORATION REPORTS FOURTH QUARTER AND FULL-YEAR 2024 RESULTS

CVS Health (CVS) PT Raised to $76 at Truist Securities

February 13, 2025 6:04 AM EST

Truist Securities analyst David MacDonald raised the price target on CVS Health (NYSE: CVS) to $76.00 (from $60.00) while maintaining a Buy rating.

The analyst comments "We remain bullish on CVS post 4Q marked by top and bottom-line beats while 25 guidance provides an attractive baseline.... More

CVS Health (CVS) Tops Q4 EPS by 19c, Beats on Revenue; Offers FY25 EPS Guidance

February 12, 2025 6:31 AM EST

CVS Health (NYSE: CVS) reported Q4 EPS of $1.19, $0.19 better than the analyst estimate of $1.00. Revenue for the quarter came in at $97.7 billion versus the consensus estimate of $96.97 billion.

GUIDANCE:

CVS Health sees FY2025 EPS of $5.75-$6.00, versus the consensus of... More